Lay Description

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia.

Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved for the disease being treated in this study. Since carfilzomib has not yet been used in this setting to treat this condition, the investigators must first find the best dose to give. The investigators are looking for the highest dose of carfilzomib that can be given safely. Therefore, not all children taking part in this study will receive the same dose of the study drug in the first part of the trial.


  • Cancers and Other Neoplasms
  • Child Health
  • Multiple Sites
IRB Number
NCT Number
Open to Enrollment


Eligible Ages
Between 6 Months and 29 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact

Regulatory Point of Contact
Jaclyn Hung
+1 (210) 450-5358

Local Recruitment Point of Contact
Jaclyn Hung
+1 (210) 450-5358

Principal Investigator
Anne-Marie Langevin